Semax and IQ claims: what the nootropic hype gets wrong

What did @b.louden06 actually say?

The creator ranked ACD856 as an "S tier" nootropic, calling it "easily one of the best" compounds on the market with cognition-enhancing ability "exceeding almost every other compound out there." They described it as a positive allosteric modulator of TRK receptors that boosts BDNF, NGF, and NT3, and credited it with reducing brain inflammation, increasing neuroplasticity, supporting learning, habit formation, and producing antidepressant-like effects. That is a substantial list of benefits attached to a compound most people have never heard of, and the tone is confident in a way that the available evidence does not yet support.

To be fair, the mechanistic description is not invented. TRK receptor modulation is a real and actively studied therapeutic target. The problem is the jump from "Alzheimer's drug in development" to universal cognitive enhancer for healthy people, which the data simply has not caught up to.

Does the science back this up?

Partially, at the mechanistic level. Not at the "S tier for everyone" level. ACD856 is a positive allosteric modulator of TrkA, TrkB, and TrkC receptors, meaning it amplifies the signal of naturally occurring neurotrophins without binding directly to them. Research from Koenig et al. (2021, Journal of Medicinal Chemistry) confirmed ACD856 enhanced BDNF and NGF signaling in preclinical models and showed cognitive benefits in rodent memory tasks. That is real data.

However, nearly all of this work is in animal models or early-phase human safety trials focused on Alzheimer's patients, not healthy adults looking for a cognitive edge. The neuroinflammation reduction claims come from extrapolating BDNF's known anti-inflammatory roles, not from direct ACD856 human studies. The antidepressant-like effects the creator mentions are consistent with TrkB agonism literature (Castrén and Bhattacharya, 2023, Nature Reviews Neuroscience), but again, these are mechanistic inferences, not clinical outcomes in healthy humans.

What did they get wrong (or right)?

They got the mechanism right. The description of TRK receptor modulation leading to elevated BDNF, NGF, and NT3 is accurate, and those neurotrophins are legitimately associated with neuroplasticity and neuroprotection. Credit where it is due: this is not pseudoscience, it is real pharmacology.

What they got wrong is the certainty. Saying ACD856 enhances cognition "exceeding almost every other compound out there" is not a finding from any published study. No head-to-head comparison in humans exists. Describing it as one of the best nootropics "on the market" is also misleading because ACD856 is not a commercially available product with a regulatory approval pathway completed. It is an investigational compound, which means access outside of clinical trials sits in a legal and safety gray zone that the video does not address at all.

The creator also omits any mention of side effects, unknown long-term profiles, or the fact that amplifying neurotrophin signaling indiscriminately is not without risk, since elevated NGF is implicated in certain pain sensitization pathways (Bannwarth and Kostine, 2014, Drugs).

What should you actually know?

ACD856 is an interesting early-stage compound with a plausible mechanism. It is not a proven cognitive enhancer for healthy people, and it is not something you should be sourcing from a gray-market peptide vendor based on a TikTok ranking. The studies that exist are promising but preliminary, conducted largely in rodents or in Alzheimer's patient populations where the risk-benefit math is very different than for a healthy 25-year-old.

The neurotrophin system is not a simple dial you turn up for better memory. BDNF signaling, for example, plays different roles depending on brain region and timing. The long-term effects of pharmacologically amplifying TRK receptor sensitivity in a healthy brain are not established. Until there are well-powered human trials in non-diseased populations, "S tier nootropic" is an opinion dressed up as a conclusion.

• ACD856 has no completed Phase III trials and no regulatory approval anywhere.
• BDNF and NGF elevation have documented benefits in neurodegeneration models, but healthy-brain optimization effects in humans remain unproven.
• Access to ACD856 outside of clinical trials is not equivalent to a vetted therapeutic intervention.

Bottom line

The creator is not making things up about the mechanism. The science on TRK modulation is real and worth watching. But ranking an investigational Alzheimer's compound as "S tier" for general cognitive enhancement, with no caveats about its development stage, unknown safety profile in healthy adults, or legal status, is the kind of confident oversimplification that leads people to make risky decisions. Interesting compound. Premature hype.